Bioventus Reports Third Quarter Financial Results
Key Highlights
- ➤Q3 revenue $142.4 million, increased 3% year over year
- ➤Non-GAAP EPS $0.17, up 13% year over year
- ➤Adjusted EBITDA $28.4 million, increased 7% year over year
- ➤Net sales guidance updated to $590 million-$595 million, growth of approximately 4%-5%
- ➤Company continues reviewing potential strategic alternatives while reaffirming Adjusted EPS guidance of $0.75-$0.79
Expert Statements
Rob Claypoole, President and Chief Executive Officer of Bioventus
“Bioventus delivered solid third-quarter results demonstrated by strong gross margin, operating cash flow and Adjusted EBITDA.”
Rob Claypoole, President and Chief Executive Officer of Bioventus
“We are encouraged by the underlying momentum across our key growth drivers and remain confident in our strategy, our portfolio and our ability to build Bioventus into a leading medtech company that delivers significant value for our shareholders, customers and employees.”
Rob Claypoole, President and Chief Executive Officer of Bioventus
“At the same time, we continue to review potential strategic alternatives for the Company as we explore all opportunities to maximize value for our shareholders.”
* Q3 reported revenue of $142.4 million increased 3% * Q3 GAAP earnings of $0.08 per diluted share compared to the prior-year period earnings of $0.05 per diluted share * Non-GAAP earnings* of $0.17 per diluted share compared to $0.15 per diluted share in the prior-year period * Cash from operations totaled $20.7 million * Company continues to review potential strategic alternatives DURHAM, N.C., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today reported financial results for the three and nine months ended September 26, 2026.
“Bioventus delivered solid third-quarter results demonstrated by strong gross margin, operating cash flow and Adjusted EBITDA,” said Rob Claypoole, Bioventus President and Chief Executive Officer. “We are encouraged by the underlying momentum across our key growth drivers and remain confident in our strategy, our portfolio and our ability to build Bioventus into a leading medtech company that delivers significant value for our shareholders, customers and employees. At the same time, we continue to review potential strategic alternatives for the Company as we explore all opportunities to maximize value for our shareholders."
Get started
Create a free account to read the full story.